Beovu® (brolucizumab-dbll)

Covered: Beovu is covered only for neovascular (wet) AMD, diabetic macular edema (DME), and the listed compendial off‑label neovascular ophthalmic conditions; other uses are excluded. Key requirements: documented diagnosis of a listed indication, administration by or under an ophthalmologist with documentation, adherence to the intravitreal dosing schedule (AMD: 6 mg monthly ×3 then q8–12 weeks; DME: 6 mg q6 weeks ×5 then q8–12 weeks), and approvals are issued for up to 12 months.

"Neovascular (Wet) Age-related Macular Degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.